维迪西妥单抗治疗转移性胃癌后发生严重皮肤药物毒性：1例报告
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report.
作者信息
Luping Zhao, Zhen Cheng, Piaopiao Li
机构信息
Department of Pharmacy, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Department of Medical Oncology, Dongyang People's Hospital, Dongyang, Zhejiang, China.
出版信息
Front Oncol. 2025 Jan 16;14:1504079. doi: 10.3389/fonc.2024.1504079. eCollection 2024.
BACKGROUND
This study reports a case of severe cutaneous toxicity in a patient with metastatic gastric cancer induced by disitamab vedotin, emphasizing the need for careful monitoring and management in such treatments.
CASE PRESENTATION
A 71-year-old female was admitted to hospital complaining of serious rashes following the first cycle of disitamab vedotin regimen for metastatic gastric cancer. The doctor diagnosedtoxic epidermal necrolysis (TEN) induced by the drug. The patient received high-dose methylprednisolone due to the side effects. This resulted in a gradual improvement of symptoms.
CONCLUSION
During the use of disitamab vedotin, patients need to be monitored for severe skin toxicity.
背景
本研究报告了1例转移性胃癌患者使用维迪西妥单抗诱导产生严重皮肤毒性的病例，强调在此类治疗中进行仔细监测和管理的必要性。
病例介绍
一名71岁女性因转移性胃癌接受维迪西妥单抗方案的首个周期治疗后，因严重皮疹入院。医生诊断为该药物引起的中毒性表皮坏死松解症（TEN）。由于副作用，患者接受了大剂量甲泼尼龙治疗。症状逐渐改善。
结论
在使用维迪西妥单抗期间，需要对患者进行严重皮肤毒性监测。
Zotero 插件